Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients

Pembrolizumab (an anti-PD1 antibody) alone or combined with chemotherapy represented the standard of care for advanced non-oncogene addicted non-small cell lung cancer (NSCLC) patients. These therapies induced early modifications of the immune response impacting the clinical outcome. Identifying ear...

詳細記述

書誌詳細

主要な著者:	Alain Gelibter, Lucrezia Tuosto, Angela Asquino, Marco Siringo, Arianna Sabatini, Ilaria Grazia Zizzari, Angelica Pace, Fabio Scirocchi, Flavio Valentino, Serena Bianchini, Salvatore Caponnetto, Donatella Paoli, Filippo Bellati, Daniele Santini, Marianna Nuti, Aurelia Rughetti, Chiara Napoletano
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2024-12-01
シリーズ:	Frontiers in Immunology
主題:	NSCLC immune checkpoint inhibitors anti-PD-1 lymphocytes CD137
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1483182/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!